Embecta Corp. acquires Owen Mumford Holdings Limited

Embecta Corp. acquired Owen Mumford Holdings Limited for Up to GBP 150 million — GBP 100 million upfront cash at closing plus up to GBP 50 million in performance-based milestone payments tied to net sales of the Aidaptus next-generation auto-injector platform, a transaction completed in May 2026, structured as all cash — share acquisition of 100% of Owen Mumford, financed with borrowings under embecta’s revolving credit facility.

Owen Mumford Holdings Limited operates in Drug-delivery devices / medical supplies, is based in Oxfordshire, United Kingdom (headquarters); approximately 80% of FY2025 revenue generated in the UK and the U.S., had revenue of about Approximately GBP 69.4 million net revenue in fiscal year 2025 (year ended September 30). Owen Mumford is a privately held, family-owned UK medical technology company founded in 1952 and headquartered in Oxfordshire, England, with more than 70 years of innovation in healthcare device development. It pioneered the first plastic autoinjector and specializes in the design and manufacture of drug delivery devices, serving as a trusted partner to many of the world’s largest pharmaceutical, biotech and healthcare organizations. Its portfolio centers on a growing pharmaceutical services business anchored by the next-generation Aidaptus auto-injector platform, alongside an established line of medical devices spanning point-of-care testing, self-injection and pelvic health. Owen Mumford generated approximately GBP 69.4 million of net revenue in its fiscal year 2025 (ended September 30), with roughly 80% of revenue earned in the UK and the U.S.

embecta described the acquisition as one that “is expected to sustainably improve embecta’s revenue growth trajectory and will accelerate our strategic transformation into a broad-based medical supplies company which provides drug delivery platforms to pharmaceutical companies and serves chronic care patients in the obesity, diabetes, autoimmune diseases and anaphylaxis markets.” The deal adds a differentiated drug-delivery platform and IP portfolio (led by Aidaptus), expands embecta’s chronic-care device offering, and lets Owen Mumford’s products reach embecta’s commercial presence in more than 100 countries.

Owen Mumford brings a differentiated, IP-protected drug-delivery platform (Aidaptus) that aligns with embecta’s GLP-1 B2B strategy and gives it a suite of autoinjector, pen-injector and pen-needle products to offer pharmaceutical partners, while its chronic-care device portfolio can scale across embecta’s 100-plus-country commercial infrastructure. embecta assumed a modest level of operational synergies in its financial model, combining Owen Mumford’s device design, molding and assembly capabilities with embecta’s large-scale manufacturing expertise and global distribution to create operational efficiencies and expanded capacity for future product programs. Acquired as a wholly owned subsidiary; integrated into embecta’s drug-delivery / medical supplies platform Dev Kurdikar, Chairman & CEO, Q2 FY2026 earnings call (May 5, 2026): “That financial discipline is what creates the capacity to pursue transactions like Owen Mumford. When we announced this acquisition in March, we noted that Owen Mumford had earned a global reputation for innovation, quality, and patient-centered design. The more time we spend with this team and this business, the more confident we are in that view. At its core, this acquisition accelerates our transformation into a broad-based medical supplies company.” CFO Jake Elguicze added that the deal is expected to be dilutive to adjusted net income in FY2027, immaterial in FY2028 and accretive thereafter, generating a high-single-digit return on invested capital by year four.